TRT, with the oversight the therapy actually requires.
Testosterone is a Schedule III controlled substance. That single fact reshapes the entire program: labs before the first fill, a live visit rather than async review, a narrower state map, a higher age floor, and quarterly monitoring that gates renewals. A platform that treats TRT like a GLP-1 refill is a compliance problem waiting to surface.
- Baseline labs before the first prescription, ordered in-flow
- Synchronous video visit, not asynchronous review
- Quarterly lab and visit cadence gating renewals
- Non-scheduled enclomiphene pathway where TRT is unavailable
Intake, then labs, then the visit that unlocks the script
Everything starts with a written intake, exactly as it does in every other category. What TRT adds after that is a lab draw and a live review, because the medication is scheduled. The order is fixed by statute and every control downstream assumes it was followed.
Men's health intake
Symptoms, history, medications, cardiovascular and prostate history, fertility intentions and consent. Fertility matters here in a way it does not in other categories.
Baseline labs
Total and free testosterone, plus a full panel, ordered inside the flow with results returning to the patient record rather than to a fax machine.
Synchronous video visit
A live visit with a provider licensed in the patient's state, who reviews the labs with the patient before any prescription is written.
Prescription and fulfillment
Approved scripts route to a licensed compounding pharmacy for cypionate injection, cream or oral, matched to the patient's state.
Quarterly monitoring
Repeat labs and a follow-up visit on a quarterly cadence, with an annual panel in place of the fourth quarterly draw.
Renewal gates
A renewal will not process without current labs and a completed visit. The gate is enforced by the platform, not by your operations team remembering.
Two pathways, because one does not cover the country
Scheduled testosterone is not available everywhere, and a brand that only sells cypionate turns away traffic it already paid for. The non-scheduled pathway captures it.
- Testosterone cypionate: DEA Schedule III, available in a limited set of states, typically restricted to patients 25 and over.
- Enclomiphene: not a controlled substance, prescribable in all 50 states and D.C., typically 18 and over.
- Intake routes the patient to the pathway their state and profile actually allow, rather than declining them.
- Both pathways carry lab requirements, but only the scheduled one requires the synchronous initial visit.
- Anastrozole and gonadorelin can be layered onto the protocol your providers define.
- Billing runs on twelve-week cycles by default, matching the lab and visit cadence rather than a monthly calendar.
Clinical and regulatory shape of the category
| Visit type | Synchronous video visit required before an initial testosterone prescription. Enclomiphene pathways can run on asynchronous review with labs. |
|---|---|
| Labs | Required before the first fill and quarterly thereafter. Renewals are gated on current results. |
| DEA scheduling | Testosterone is Schedule III. Enclomiphene is not a controlled substance. |
| State availability | Scheduled TRT is available in a limited subset of states. The non-scheduled enclomiphene pathway covers all 50 plus D.C. |
| Typical age floor | Commonly 25 and over for scheduled TRT; 18 and over for enclomiphene. |
| Refill cadence | Twelve-week cycles, with an annual panel replacing the fourth quarterly lab draw. |
Oversight is wired in, not bolted on
Prescriptions are involved, so clinical oversight is not a setting you switch on. It is wired into the workflow, and there is no configuration in which it is absent.
Provider review the platform enforces
Nothing is prescribed until a clinician holding a licence in that patient's state signs off. There is no path through the software that reaches a pharmacy without it.
State rules in the routing layer
Which questions get asked, which clinician picks up the case and which pharmacy fills it are all decided by where the patient is sitting. Texas and California can run as different programs without you maintaining two of anything.
An audit trail you can query
Every intake version, clinical decision, script and pharmacy handoff is written to the patient record and stays queryable. When someone asks what happened in March, you answer it in a minute.
Men's health operators ask us
Not with scheduled testosterone. Cypionate is DEA Schedule III and available in a limited subset of states, usually with an age floor around 25. The non-scheduled enclomiphene pathway is prescribable in all 50 states and D.C., so intake routes patients to whichever pathway their state and profile allow rather than declining them outright.
Put your men's health brand on clinical rails
Labs in-flow, live visits where the law requires them, renewals gated on current results. Live in 5 days.